In silico Study of New Vascular Endothelial Growth Factor Receptor Inhibitors for The Treatment of Hepatocellular Carcinoma


  • Marwan Imad Jihad Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mustansiriyah, Baghdad, Iraq
  • Monther Faisal Mahdi Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mustansiriyah, Baghdad, Iraq



Hepatocellular carcinoma, Sorafenib, Vascular Endothelial Growth Factor, Cambridge Crystallographic Data Centre.


Novel therapeutics are desperately needed for the difficult-to-treat and very lethal malignancy known as hepatocellular carcinoma (HCC). The first drug now authorized for the treatment of individuals with advanced HCC is sorafenib. To find novel Vascular Endothelial Growth Factor Receptor Inhibitors as prospective candidate therapeutics for HCC, an in-silico technique was used in this case. Docking investigations were conducted using the GOLD Suite (v. 5.7.1) from the Cambridge Crystallographic Data Centre (CCDC). The docking/scoring methods of CCDC were validated by reproducing the docking interactions and poses of Sorafenib. Based on their PLP fitness, compounds I–X and sorafenib were graded for their ability to inhibit VEGF. Compounds II, III and VIII among other ligands exhibit higher binding energies than the standard drug sorafenib that give PLP fitness value (80.4).


- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018;391(10125):1023-75.

- Rybakova Y, Gonzalez JT, Bogorad R, Chauhan VP, Dong YL, Whittaker CA, et al. Identification of a long non-coding RNA regulator of liver carcinoma cell survival. Cell death & disease. 2021;12(2):1-14.

- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.

- Tabor E. Hepatocellular carcinoma: global epidemiology. Digestive and Liver Disease. 2001;33(2):115-7.

- Shah UA, Joshi HV, Patel JK, Savjani J, Patel VK, Choudhary K, et al. Molecular docking studies of novel dihydro Pyrimidine derivatives as potential antibacterial agents.

- Abbas WAK, Alzubaidi SHA, Aljaleeli AND, Al-Mugdadi SFH. Vascular Endothelial Growth Factor (VEGF-C) Protein Expression Related with Lymphangiogensis in Iraqi Cervical Cancer Patients. Al Mustan-siriyah Journal of Pharmaceutical Sciences. 2019;19(4):28-40.

- Talib WH, Al Kury LT. Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53-dependent apoptosis and inhibiting VEGF expression. Biome-dicine & Pharmacotherapy. 2018;107 :1488-95.

- Hajalsiddig TT, Osman ABM, Saeed AE. 2D-QSAR modeling and molecular docking studies on 1 H-Pyrazole-1-carbothioamide derivat-ives as EGFR kinase inhibitors. ACS omega. 2020;5(30):18662-74.

- Allawi MM, Mahdi MF, Raauf AM. Synthesis, anti-inflammatory, molecu-lar docking and ADME studies of new derivatives of ketoprofen as cycloox-ygenases inhibitor. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2019;19(4):125-39.

- Khalifa NM, Al-Omar MA, Alkahtani HM, Bakheit AH. Kinase Inhibitors of Novel Pyridopyrimidinone Candidates : Synthesis and In Vitro Anticancer Properties. Journal of Chemistry. 2019;2019.

- Ibrahim MT, Uzairu A, Shallangwa GA, Uba S. In-silico activity prediction and docking studies of some 2, 9-disubstituted 8-phenylthio /phenylsulfinyl-9h-purine derivatives as Anti-proliferative agents. Heliyon. 2020;6(1):e03158.

- Muhsin YF, Alwan SM, Khan AK. Design, Molecular Docking, Synthesis of Aromatic Amino Acids Linked to Cephalexin. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2021;21 (3):25-34.

- Lee A, Hong S, Kim D. KRDS: a web server for evaluating drug resistance mutations in kinases by molecular docking. Journal of cheminformatics. 2018;10(1):1-10.